- Home
- NMRA vs AQST Comparison
NMRA vs AQST Comparison
Compare NMRA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- AQST
- Stock Information
- Founded
- NMRA 2019
- AQST 2004
- Country
- NMRA United States
- AQST United States
- Employees
- NMRA N/A
- AQST N/A
- Industry
- NMRA
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- AQST Health Care
- Exchange
- NMRA Nasdaq
- AQST Nasdaq
- Market Cap
- NMRA 268.5M
- AQST 390.4M
- IPO Year
- NMRA 2023
- AQST 2018
- Fundamental
- Price
- NMRA $1.62
- AQST $5.05
- Analyst Decision
- NMRA Buy
- AQST Strong Buy
- Analyst Count
- NMRA 8
- AQST 7
- Target Price
- NMRA $7.14
- AQST $10.29
- AVG Volume (30 Days)
- NMRA 383.3K
- AQST 2.4M
- Earning Date
- NMRA 11-11-2025
- AQST 11-03-2025
- Dividend Yield
- NMRA N/A
- AQST N/A
- EPS Growth
- NMRA N/A
- AQST N/A
- EPS
- NMRA N/A
- AQST N/A
- Revenue
- NMRA N/A
- AQST $44,132,000.00
- Revenue This Year
- NMRA N/A
- AQST N/A
- Revenue Next Year
- NMRA N/A
- AQST $38.71
- P/E Ratio
- NMRA N/A
- AQST N/A
- Revenue Growth
- NMRA N/A
- AQST N/A
- 52 Week Low
- NMRA $0.61
- AQST $2.12
- 52 Week High
- NMRA $17.19
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- NMRA 47.71
- AQST 66.65
- Support Level
- NMRA $1.60
- AQST $4.75
- Resistance Level
- NMRA $1.70
- AQST $5.60
- Average True Range (ATR)
- NMRA 0.09
- AQST 0.29
- MACD
- NMRA -0.01
- AQST 0.09
- Stochastic Oscillator
- NMRA 8.51
- AQST 70.59
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.